Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Official Title Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma
Alliance for Clinical Trials in Oncology
26 participants
Nov 27, 2024
INTERVENTIONAL
Conditions
Summary
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Given IV
Given IV
Undergo surgery
undergo CT
Undergo MRI
Undergo PET
Locations(131)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05647265